← Scroll for more →
Intellia Therapeutics, Inc. (NTLA)
In Vitro & In Vivo Diagnostic Substances
Latest Price
$12.47
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
5.21
P/B Ratio
2.39
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 16.88M | $285.0M | 12.05% | +2.37M | 2026-06-30 |
| BlackRock, Inc. | 15.41M | $260.0M | 11.01% | +3.25M | 2026-06-30 |
| State Street Corp | 9.23M | $156.0M | 6.60% | +2.31M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 7.33M | $124.0M | 5.24% | +1.11M | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 6.44M | $109.0M | 4.60% | +715.1K | 2026-06-30 |
| Vanguard Capital Management LLC | 6.03M | $102.0M | 4.31% | +944.5K | 2026-06-30 |
| Two Sigma Investments, LP | 5.24M | $88.0M | 3.74% | -- | 2026-06-30 |
| FMR LLC | 4.77M | $80.0M | 3.41% | +2.71M | 2026-06-30 |
| RA Capital Management, L.P. | 4.53M | $76.0M | 3.23% | -- | 2026-06-30 |
| Regeneron Pharmaceuticals, Inc. | 3.70M | $62.0M | 2.64% | -- | 2026-06-30 |